KORU Medical Systems (KRMD) Projected to Post Earnings on Thursday

KORU Medical Systems (NASDAQ:KRMD) is projected to issue its Q4 2025 results after the market closes on Thursday, March 12th. Analysts expect KORU Medical Systems to post earnings of ($0.02) per share and revenue of $10.90 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:30 PM ET.

KORU Medical Systems Stock Performance

Shares of NASDAQ KRMD opened at $4.61 on Tuesday. The company has a current ratio of 2.48, a quick ratio of 1.92 and a debt-to-equity ratio of 0.01. KORU Medical Systems has a 12 month low of $1.86 and a 12 month high of $6.61. The stock has a 50 day moving average of $5.21 and a 200-day moving average of $4.80. The company has a market capitalization of $213.54 million, a P/E ratio of -57.63 and a beta of 0.47.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets increased its holdings in shares of KORU Medical Systems by 52.1% during the third quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock worth $39,000 after purchasing an additional 3,478 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of KORU Medical Systems in the second quarter valued at approximately $59,000. Occudo Quantitative Strategies LP bought a new stake in shares of KORU Medical Systems in the fourth quarter valued at approximately $127,000. Invesco Ltd. acquired a new stake in KORU Medical Systems during the second quarter worth approximately $80,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in KORU Medical Systems during the second quarter worth approximately $83,000. Institutional investors and hedge funds own 58.60% of the company’s stock.

Analyst Upgrades and Downgrades

KRMD has been the subject of several research reports. Wall Street Zen raised KORU Medical Systems from a “buy” rating to a “strong-buy” rating in a report on Monday, January 12th. Lake Street Capital raised their target price on shares of KORU Medical Systems from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, December 22nd. Craig Hallum reaffirmed a “buy” rating and set a $7.00 target price on shares of KORU Medical Systems in a report on Tuesday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of KORU Medical Systems in a report on Thursday, January 22nd. Finally, Canaccord Genuity Group upped their target price on KORU Medical Systems from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $6.13.

KORU Medical Systems Company Profile

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.